Quick Takeaways: Why It Matters? VetrixBio is testing a dual-action osteoarthritis therapy that targets both pain (NGF/TrkA) and cartilage degradation (ADAMTS-5) in dogs, rather than just providing analgesia. The clinical data in aged Beagles shows a single...
Quick Takeaways: Why It Matters? Lenivia strengthens Zoetis’ lead in monoclonal antibody–based pain management for dogs by adding a longer-acting OA option to its portfolio. Market-wise, a single injection providing up to three months of osteoarthritis pain...
Quick Takeaways Why It Matters? Piclidenoson could open a new, higher‑value segment in the canine osteoarthritis market as one of the first oral, potentially disease‑modifying options rather than just another pain reliever. If the ongoing Phase II trial confirms the posit...
